Immunome (IMNM) Competitors $14.01 +0.19 (+1.37%) Closing price 04:00 PM EasternExtended Trading$14.00 0.00 (-0.04%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMNM vs. KYMR, PTGX, CRNX, ZLAB, AKRO, ACAD, AAPG, MIRM, LNTH, and MENSShould you be buying Immunome stock or one of its competitors? The main competitors of Immunome include Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), Crinetics Pharmaceuticals (CRNX), Zai Lab (ZLAB), Akero Therapeutics (AKRO), ACADIA Pharmaceuticals (ACAD), Ascentage Pharma Group International (AAPG), Mirum Pharmaceuticals (MIRM), Lantheus (LNTH), and Jyong Biotech (MENS). These companies are all part of the "pharmaceutical products" industry. Immunome vs. Its Competitors Kymera Therapeutics Protagonist Therapeutics Crinetics Pharmaceuticals Zai Lab Akero Therapeutics ACADIA Pharmaceuticals Ascentage Pharma Group International Mirum Pharmaceuticals Lantheus Jyong Biotech Immunome (NASDAQ:IMNM) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment. Is IMNM or KYMR more profitable? Kymera Therapeutics has a net margin of -616.03% compared to Immunome's net margin of -1,687.08%. Kymera Therapeutics' return on equity of -31.60% beat Immunome's return on equity.Company Net Margins Return on Equity Return on Assets Immunome-1,687.08% -76.10% -65.14% Kymera Therapeutics -616.03%-31.60%-27.12% Which has better valuation and earnings, IMNM or KYMR? Kymera Therapeutics has higher revenue and earnings than Immunome. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunome$9.04M134.89-$292.96M-$3.08-4.55Kymera Therapeutics$47.07M85.51-$223.86M-$3.47-16.22 Which has more risk and volatility, IMNM or KYMR? Immunome has a beta of 1.94, indicating that its share price is 94% more volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.26, indicating that its share price is 126% more volatile than the S&P 500. Do analysts rate IMNM or KYMR? Immunome currently has a consensus price target of $23.20, suggesting a potential upside of 65.60%. Kymera Therapeutics has a consensus price target of $61.26, suggesting a potential upside of 8.83%. Given Immunome's higher possible upside, analysts clearly believe Immunome is more favorable than Kymera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunome 1 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.82Kymera Therapeutics 1 Sell rating(s) 1 Hold rating(s) 17 Buy rating(s) 2 Strong Buy rating(s) 2.95 Do insiders & institutionals hold more shares of IMNM or KYMR? 44.6% of Immunome shares are owned by institutional investors. 7.7% of Immunome shares are owned by insiders. Comparatively, 16.0% of Kymera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media favor IMNM or KYMR? In the previous week, Kymera Therapeutics had 1 more articles in the media than Immunome. MarketBeat recorded 4 mentions for Kymera Therapeutics and 3 mentions for Immunome. Kymera Therapeutics' average media sentiment score of 0.47 beat Immunome's score of 0.00 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kymera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryKymera Therapeutics beats Immunome on 12 of the 17 factors compared between the two stocks. Get Immunome News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMNM vs. The Competition Export to ExcelMetricImmunomeMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.22B$3.37B$6.10B$10.65BDividend YieldN/A2.29%5.70%4.74%P/E Ratio-4.5521.7185.5527.59Price / Sales134.89477.40622.26138.47Price / CashN/A47.6737.7861.77Price / Book6.1710.1413.136.76Net Income-$292.96M-$52.31M$3.30B$275.88M7 Day Performance23.54%6.72%5.29%3.72%1 Month Performance49.04%15.01%9.94%10.22%1 Year Performance8.60%29.34%87.78%35.86% Immunome Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMNMImmunome1.4559 of 5 stars$14.01+1.4%$23.20+65.6%+11.0%$1.20B$9.04M0.0040Analyst ForecastGap UpKYMRKymera Therapeutics1.9836 of 5 stars$57.55-0.6%$61.26+6.5%+34.8%$4.14B$47.07M-16.58170Analyst ForecastPTGXProtagonist Therapeutics2.3066 of 5 stars$64.14-1.1%$68.36+6.6%+49.5%$4.03B$434.43M91.63120Analyst ForecastCRNXCrinetics Pharmaceuticals3.9068 of 5 stars$41.68+2.0%$74.45+78.6%-17.9%$3.85B$1.04M-10.14210Analyst ForecastZLABZai Lab2.8607 of 5 stars$33.31-1.3%$56.35+69.2%+24.8%$3.77B$398.99M-16.331,869Positive NewsAnalyst ForecastAKROAkero Therapeutics3.7113 of 5 stars$46.04-0.1%$81.14+76.2%+72.0%$3.69BN/A-23.0230Positive NewsAnalyst ForecastACADACADIA Pharmaceuticals4.4806 of 5 stars$21.59-1.0%$29.12+34.9%+46.2%$3.68B$1.02B16.23510Analyst RevisionAAPGAscentage Pharma Group InternationalN/A$39.86+1.2%N/AN/A$3.67B$134.35M0.00600News CoverageMIRMMirum Pharmaceuticals3.3667 of 5 stars$72.53-0.6%$76.50+5.5%+90.3%$3.66B$336.89M-59.94140Positive NewsAnalyst ForecastLNTHLantheus4.6507 of 5 stars$52.70-2.1%$85.50+62.2%-51.4%$3.66B$1.53B14.02700Analyst ForecastGap DownMENSJyong BiotechN/A$52.01+8.4%N/AN/A$3.65BN/A0.0031Analyst Forecast Related Companies and Tools Related Companies KYMR Competitors PTGX Competitors CRNX Competitors ZLAB Competitors AKRO Competitors ACAD Competitors AAPG Competitors MIRM Competitors LNTH Competitors MENS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMNM) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored3 Major A.I. Threats That Could Upend the U.S. EconomyThe media's calling Artificial Intelligence a "revolution," but for many Americans, the real impact might actu...Goldco Precious Metals | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunome, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunome With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
